Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02521376 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
A Phase 1 study of Oncology, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 6
- Study locations
NCT02521376 is a Phase 1 study of Oncology that has completed, run by Gilead Sciences. The registered enrollment target is 56 participants, below the 525-participant average among 24 other Oncology trials with a reported enrollment target (89% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT02521376, a Phase 1 study of Oncology, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 6
- Study locations
Study Summary
The primary objective of this study is to evaluate the pharmacokinetics of entospletinib (ENTO) and/or its metabolites (if applicable) in participants with impaired hepatic function (stratified by smoking status, as appropriate) relative to matched, healthy controls.
Conditions Studied
Interventions
- DRUG Entospletinib
Study Locations (6)
Florida
- Clinical Pharmacology of Miami, Inc. (CPMI) - Miami
- Orlando Clinical Research Center - Orlando
Other
- APEX GmBH - Munich
- Auckland Clinical Studies - Auckland
Minnesota
- DaVita Clinical Research - Minneapolis
Texas
- The Texas Liver Institute - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2015-11-16 |
| Est. Completion | 2017-10-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02521376
The ClinicalTrials.gov registry entry for NCT02521376 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 525-participant average among 24 other Oncology trials with a reported enrollment target (89% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Oncology appearing as the primary indexed condition, and to 1 intervention - of which Entospletinib is the first listed.
NCT02521376 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Florida, Other, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02521376 about?
NCT02521376 is a clinical study titled "Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function". The primary objective of this study is to evaluate the pharmacokinetics of entospletinib (ENTO) and/or its metabolites (if applicable) in participants with impaired hepatic function (stratified by smoking status, as appropriate) relative to matched, healthy controls.
What is the current status of trial NCT02521376?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2015-11-16. Estimated completion is 2017-10-25.
What conditions does trial NCT02521376 study?
This clinical trial studies the following conditions: Oncology.
What interventions are being tested in trial NCT02521376?
The interventions under investigation include: Entospletinib (DRUG).
Who is sponsoring clinical trial NCT02521376?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02521376 being conducted?
This trial has 6 study locations across Florida, Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oncology
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of AMG 820 in Subjects With Advanced Solid Tumors
COMPLETED · Phase 1
-
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
COMPLETED · Phase 1
-
A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.